Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from LTR Pharma Limited ( (AU:LTP) ).
LTR Pharma Limited has notified the market of the issue of new unquoted equity securities under its employee incentive arrangements, including 1,365,327 performance rights and a total of 6.2 million options across two new option classes. The options are exercisable at set prices and expire in December 2028 and December 2029 respectively, signalling the company’s ongoing use of long‑term equity incentives to align staff and management with shareholder interests, support retention, and potentially expand its capital base if the options are exercised in future.
More about LTR Pharma Limited
LTR Pharma Limited is an ASX-listed pharmaceutical company (code: LTP). The company operates in the life sciences sector, focusing on the development and commercialisation of pharmaceutical products, and uses equity-based incentives as part of its employee remuneration and retention strategy.
Average Trading Volume: 404,948
Technical Sentiment Signal: Buy
Current Market Cap: A$94.46M
For an in-depth examination of LTP stock, go to TipRanks’ Overview page.